For other salt forms please inquire.
According to Schwede et al. (2015), Sp-8-BnT-cAMPS potently and selectively activates Epac2 over Epac1 both in vitro and in vivo (in vitro AC50 Epac2 = 0.1 μM (1.8 µM for cAMP) and rel. kmax = 7.7 (1 for cAMP)). At concentrations of 25 to 100 µM, it potentiates glucose-induced insulin secretion from primary human islets. Sp-8-BnT-cAMPS has reduced potency to activate PKA. Detailed technical information available. Reference: Schwede et al., PLoS Biol., 13(1): e1002038 (2015) (Link to PLoS Biology).
Related products: Biolog also offers Sp-8-BnT-2'-O-Me-cAMPS (Cat. No. B 056 / "S-223") which has reduced potency compared to Sp-8-BnT-cAMPS, but efficiently discriminates against PKA, as well as the well-established Epac agonist 8-pCPT-2'-O-Me-cAMP (Cat. No. C 041) which selectively activates Epac1 over Epac2 (Schwede et al. 2015).
|Cat. No.||B 046|
|Purity||> 98% HPLC|
|Storage temperature||-20°C / -4°F|
|Molecular formula||C₁₇H₁₇N₅O₅PS₂ · Na|
|Molecular weight [g/mol]||489.5|
|cAMP modified at the exocyclic oxygen||axial (Sp-)|
|Target||PKA (cAK) Activator|
|Absorption max [nm]||283|
|Molar extinction coefficient ε [L·mol⁻¹·cm⁻¹]||17100|